INTRINSIC: A Multi-Arm Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer

Sponsor: Hoffmann-La Roche

Full Title
Protocol WO42758: A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer

Study Treatment
Oral KRAS G12C inhibitor Divarasib in combination with standard of care chemotherapy regimen FOLFOX or FOLFIRI

Eligibility/Info

• Stage IV colon or rectal adenocarcinoma
• KRAS G12C mutation and the absence of another oncogenic mutation
• No prior systemic therapy in the advanced/metastatic setting

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage